However, the absolute number of monocytes, and the numbers of CD14+highCD16−, CD14+highCD16+ and CD14+lowCD16+ subset cells, in peripheral blood would appear to provide practical biomarkers for predicting the response to MTX of treatment-naive patients with RA. Here, CD14 is linked to rheumatoid arthritis.